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Background: With the development of new direct acting antiviral (DAA) therapy for hepatitis 
C, the backbone peginterferon alpha used may be of importance in maximizing treatment 
outcomes. To this end, the rates of sustained virologic response (SVR), relapse, and treatment 
discontinuation among hepatitis C genotype 1-infected patients given peginterferon alpha-2a 
plus ribavirin or peginterferon alpha-2b plus ribavirin were determined using a meta-analysis.
Methods: Randomized trials examining peginterferon alpha-2a or peginterferon alpha-2b co-
administered with ribavirin for 48 weeks were included. Data were extracted on SVR, relapse, 
and treatment discontinuations for treatment-naïve and treatment-experienced patients. Pooled 
proportions using fixed and random effects meta-analysis were calculated.
Results: Twenty-six trials provided data on patients treated with peginterferon alpha-2a plus 
ribavirin, and 19 trials provided data on patients treated with peginterferon alpha-2b plus ribavirin. 
Five trials were direct head-to-head evaluations. In the subset of trials that included head-to-head 
  evaluations, no significant differences were observed between the two treatments for treatment-naïve 
(relative risk [RR]: 1.07, 95% confidence intervals [CI]: 0.97–1.18) and treatment-experienced 
patients (RR: 1.27, 95% CI: 0.58–2.77). Using only active trial arms, a larger proportion of the 
  treatment-naïve patients who were provided peginterferon alpha-2a plus ribavirin achieved a SVR 
(47%), which is greater than that of treatment-naïve patients who were provided peginterferon alpha-
2b plus ribavirin (40% SVR achievement); however, a larger proportion of   treatment-experienced 
patients who were provided peginterferon alpha-2b plus ribavirin achieved a SVR (16%) when 
compared with treatment-experienced patients given peginterferon alpha-2a plus ribavirin (12% 
SVR achievement). A larger proportion of relapses occurred among both treatment-naïve and 
treatment-experienced patients given peginterferon alpha-2a plus ribavirin, when compared with 
treatment-naïve and treatment-experienced patients taking peginterferon alpha-2b plus ribavirin. The 
proportion of patients discontinuing treatment was greater among treatment-naïve patients taking 
peginterferon alpha-2a plus ribavirin, but smaller among treatment-experienced patients.
Conclusion: There are small differences in treatment outcomes for different types of 
  peginterferon-alpha. Patient status and complexity of administration may differentiate clinical 
outcomes.
Keywords: hepatitis C, genotype 1, peginterferon, ribavirin, sustained virologic response, 
meta-analysis
Introduction
The efficacy of peginterferon (also known as pegylated interferon) dosed concomitantly 
with ribavirin as a treatment for hepatitis C is influenced by patient clinical and genetic char-
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acteristics, adherence, initial virologic response to treatment, 
and duration of therapy. It is possible that differences in treat-
ment efficacy may also occur according to the type of peginter-
feron used (peginterferon alpha-2a or peginterferon alpha-2b). 
It is noteworthy that findings from a recently conducted large-
scale randomized trial indicate that peginterferon alpha-2a plus 
ribavirin and peginterferon alpha-2b plus ribavirin do not differ 
significantly in terms of sustained virologic response (SVR) 
and tolerability when provided to treatment-naïve genotype 
1-infected hepatitis C patients.1 The finding from a single 
clinical trial, however, is rarely definitive.
Direct-acting antivirals (DAAs) in combination with 
peginterferon and ribavirin have dramatically improved 
treatment outcomes in patients infected with genotype 1 
hepatitis C.2,3 Despite the impact of these individual medica-
tions on treatment outcomes, it is possible that the specific 
peginterferon alpha used as a backbone may help to maximize 
the likelihood of therapeutic success, and therefore, this ques-
tion remains relevant to current hepatitis C management. In 
the current study, the rate of SVR, treatment relapse, and 
treatment discontinuations in hepatitis C genotype 1-infected 
patients receiving either standard-dose peginterferon alpha-
2a or peginterferon alpha-2b concomitantly with standard 
dose ribavirin were determined by applying a meta-analysis 
of all available treatment arms of the specified drug combina-
tions from published randomized trials.
Methods
Eligibility
The arms of randomized trials involving standardized doses 
of peginterferon alpha-2a or peginterferon alpha-2b concomi-
tantly administered with a standardized dose of ribavirin were 
included in the current study. Only trial arms that provided 
details on the number of genotype 1 patients allocated to 
treatment were included. Approved dosing standards were 
according to the European Association for the Study of the 
Liver (EASL) (alpha-2b 1.5 mcg per kg subcutaneously once 
weekly, alpha-2a 180 mcg subcutaneously once weekly, 
ribavirin total daily dose of 600–1400 mg depending upon 
weight). Trial arms were only included if they assessed 
48 weeks of treatment administration. Studies had to be 
conducted in North America or Europe, as genotype 1 is the 
most common genotype in these regions.
Trial arms were excluded if they assessed loading doses 
and/or non-standardized doses of peginterferon or ribavirin, 
as were trials that recruited coinfected patients (eg, those with 
HIV or hepatitis B) and/or trials that exclusively recruited 
specific subgroups (eg, patients with compensated   cirrhosis). 
Trial arms that included DAAs or additional hepatitis C 
  medications were also excluded, as were any that did not 
break down outcomes exclusively for genotype 1 patients.
Search strategy
A search strategy was developed in consultation with a 
  medical librarian. The included search terms were peginter-
feron OR peg-interferon OR pegylated interferon AND 
  ribavirin AND hepatitis C. The search was limited to ran-
domized trials in humans. Two investigators (EM and ED) 
searched independently, in duplicate, the following databases 
(from inception to week 32 [August 8–14], 2011):   MEDLINE, 
EMBASE, Cochrane CENTRAL, AMED, CINAHL, 
TOXNET, Development and Reproductive Toxicology, 
  Hazardous Substances Databank, Psych-info, and Web of 
Science. Databases that include the full text of journals were 
also searched   (ScienceDirect and Ingenta, including articles 
in full text from approximately 1700 journals since 1993). In 
addition, the bibliographies of published systematic reviews 
and relevant included trials were also searched. Searches 
were not limited by language, sex, or age.
Study selection
Two investigators (EM and ED) working independently, 
in duplicate, scanned all abstracts and obtained the full text 
reports of records indicating that the study was a randomized 
control trial evaluating peginterferon alpha-2a plus ribavirin 
or peginterferon alpha-2b plus ribavirin on the outcomes of 
interest. After obtaining full reports of the candidate studies, 
the same investigators independently assessed eligibility via 
full text review. Where required, a third investigator (CC) 
provided arbitration.
Data abstraction and endpoints
Two investigators (EM and ED) working independently, in 
duplicate, abstracted data. Data were abstracted only from 
the peginterferon-2a plus ribavirin or peginterferon-2b plus 
ribavirin treatment arms 48 weeks in length. Data on the 
primary outcome of interest (that is, SVR, which was defined 
as an undetectable HCV RNA at the end of the 24-week post 
therapy follow-up period) was abstracted, as well as data on 
the secondary outcomes of interest (the proportion of patients 
relapsing, which was defined as a recurrence of HCV RNA 
within the 24-week post therapy follow-up period), and the 
proportion of patients discontinuing   treatment (defined as 
the discontinuation of all assigned study drugs during the 
set treatment period). The following study characteristics 
were also abstracted: study setting, study year, study 
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duration, and dosing regimens. Data were abstracted for 
both treatment-naïve patients (defined as patients with no 
exposure to peginterferon alpha plus ribavirin) and treatment-
experienced patients (defined as patients with prior exposure 
to   peginterferon alpha plus ribavirin).
Data analysis
In order to assess inter-rater reliability on inclusion of articles, 
the Phi statistic (ϕ) was calculated to provide a measure of 
inter-observer agreement independent of chance. The pooled 
weighted proportions were calculated by first stabilizing the 
variances of the raw proportions (r/n) using a Freeman–Tukey 
type arcsine square root transformation, and applying a fixed 
effects model. This was supplemented with a random effects 
model. While several methods of pooling proportions exist, 
the Freeman–Tukey method works well with both fixed and 
random effects meta-analyses and truncates at zero. This 
is a variance-stabilizing transformation that removes the 
dependence of the variance on the mean of the transformed 
proportion (ie, it corrects for over dispersion). Assessing 
  heterogeneity in pooled proportions may be misleading, 
therefore the I2 value is reported where applicable, and is 
interpreted with caution. In the case of trials that permitted a 
head-to-head evaluation, fixed and random effects relative risk 
meta-analyses were applied. Analyses were conducted using 
StatsDirect (v 2.5.2; StatsDirect Ltd, Cheshire, UK) and Com-
prehensive Meta-Analysis (v 2; Biostat, Englewood, NJ).
Results
Twenty-six trials provided data on patients treated with 
peginterferon alpha-2a plus ribavirin.1,3–27 Eighteen of 
these   trials were conducted among treatment-naïve 
patients,1,3,10–23,26,27 and eight were conducted among treatment-
experienced patients.4–9,24,25 The characteristics of these 
trials are presented in Table 1. Nineteen trials provided 
data on patients treated with peginterferon alpha-2b plus 
ribavirin.1,2,24–40 Thirteen of these trials were conducted among 
treatment-naïve patients,1,2,26,27,32–40 and six were conducted 
among treatment-experienced patients.24,25,28–31 The character-
istics of these trials are presented in Table 2. Five trials were 
direct head-to-head evaluations of peginterferon alpha-2a plus 
ribavirin and peginterferon alpha-2b plus ribavirin.1,24–27
Forty-seven trials retrieved for detailed evaluation were 
excluded. The reasons for exclusion of these trials were that 
20 assessed treatment combinations and/or treatment dos-
ings that were not of interest,41–52 twelve combined outcomes 
Table 1 Trials reporting on outcomes among patients treated with peginterferon alpha-2a plus ribavirin
Trial Region Treatment  
duration (weeks)
Treatment  
experience
N Peginterferon alpha-2a  
dose (μg/week)
Ribavirin dose   
(mg/day)
Fried et al13 International 48 Naïve 298 180 1000–1200
Hadziyannis et al14 International 48 Naïve 271 180 1000–1200
Herrine et al5 North America 48 Experienced 25 180 800–1000
Berg et al4 International 48 Experienced 35 180 1000–1200
Ferenci et al11 Europe 48 Naïve 95 180 1000–1200
Yenice et al27 Europe 48 Naïve 34 180 800–1200
Diago et al10 Europe 48 Naïve 475 180 1000–1200
Scotto et al24 Europe 48 Experienced 37 180 800–1200
Scotto et al25 Europe 48 Experienced 45 180 800–1200
von wagner et al21 Europe 48 Naïve 352 180 1000–1200
Zeuzem et al23 International 48 Naïve 114 180 1000–1200
Hezode et al15 Europe 48 Naïve 82 180 1000–1200
Jensen et al6 International 48 Experienced 284 180 1000–1200
McHutchison et al1 North America 48 Naïve 1035 180 1000–1200
McHutchison et al3 North America 48 Naïve 75 180 1000–1200
Roberts et al20 Australia 48 Naïve 438 180 1000–1200
Rustgi et al8 North America 48 Experienced 104 180 1000–1200
Ferenci et al12 Europe 48 Naïve 127 180 1000–1200
Marcellin et al17 International 48 Naïve 212 180 1000–1200
McHutchison et al7 International 48 Experienced 114 180 1000–1200
Mendez-Navarro et al18 North America 48 Naïve 63 180 1000–1200
Reddy et al19 International 48 Naïve 189 180 1400–1600
Rumi et al26 Europe 48 Naïve 91 180 1000–1200
Zeuzem et al22 International 48 Naïve 441 180 1000–1200
Jacobson et al16 International 48 Naïve 361 180 1000–1200
Zeuzem et al9 International 48 Experienced 132 180 1000–1200
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for genotype 1 with other genotypes,53–64 nine did not   provide 
extractable SVR data of interest,65–73 and six assessed 
  induction treatments.74–79 Figure 1 shows a schematic of the 
trial selection process.
All 18 trials assessing peginterferon alpha-2a plus 
ribavirin among treatment-naïve patients provided data on 
SVR;1,3,10–23,26,27 eleven of these also provided data on the rate 
of relapse,1,3,12,15–20,22,23 and twelve provided data on   treatment 
discontinuations.1,3,10,11,15,16,18–23 All 13 trials assessing 
peginterferon alpha-2b plus ribavirin among treatment-naïve 
patients provided data on SVR;1,2,26,27,32–40 nine also provided 
data on the rate of relapse,1,2,33–37,39,40 and seven provided 
Table 2 Trials reporting on outcomes among patients treated with peginterferon alpha-2b plus ribavirin
Trial Region Treatment  
duration (weeks)
Treatment  
experience
N Peginterferon alpha-2b  
dose (μg/kg/week)
Ribavirin dose   
(mg/day)
Scotto et al38 Europe 48 Naïve 26 1.5 800–1200
Mathew et al30 North America 48 Experienced 59 1.5 1000–1200
Maynard et al31 Europe 48 Experienced 82 1.5 800–1200
Yenice et al27 Europe 48 Naïve 34 1.5 800–1200
Jacobson et al35 North America 48 Naïve 1313 1.5 800–1400
Marcellin et al29 Europe 48 Experienced 3 1.5 800–1200
Shiffman et al39 North America 48 Naïve 48 1.5 800–1400
Sjogren et al40 North America 48 Naïve 29 1.5 1000–1200
Scotto et al24 Europe 48 Experienced 40 1.5 800–1200
Scotto et al25 Europe 48 Experienced 47 1.5 800–1200
Benhamou et al32 International 48 Naïve 226 1.5 1000–1200
Berg et al33 Europe 48 Naïve 225 1.5 800–1400
McHutchison et al1 North America 48 Naïve 1019 1.5 800–1400
Buti et al34 International 48 Naïve 86 1.5 800–1400
Kwo et al36 North America and Europe 48 Naïve 104 1.5 800–1400
Poordad et al37 North America 48 Naïve 70 1.5 800–1400
Rumi et al26 Europe 48 Naïve 87 1.5 800–1200
Bacon et al28 North America and Europe 48 Experienced 80 1.5 600–1400
Poordad et al2 North America and Europe 48 Naïve 344 1.5 600–1400
343 publications identified and screened 
87 retrieved for detailed evaluation 
256 excluded 
47 excluded: 
– 20 treatment combinations and/or dosing
not of interest  
– 12 combined outcomes for genotype 1
with other genotypes  
– 9 did not provided extractable SVR data
of interest  
– 6 assessed induction treatments 
40 studies included 
– 21 assessed peginterferon alpha-2a plus
ribavirin 
– 14 assessed peginterferon alpha-2b plus
ribavirin 
– 5 assessed both peginterferon alpha-2a
plus ribavirin and peginterferon alpha-2b
plus ribavirin   
Figure 1 Study flow diagram.
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data on treatment discontinuations.1,33,34,36–38,40 Table 3 shows 
the results of the fixed-effects proportional meta-analysis 
of SVR, relapse, and discontinuation for treatment-naïve 
patients (refer to the Appendix for the random-effects 
models). The pooled estimate of SVR among naïve patients 
treated for 48 weeks was 47% (95% confidence interval 
[CI]: 45%–48%) for those treated with peginterferon alpha-
2a plus ribavirin, and 40% (95% CI: 38%–41%) for those 
treated with peginterferon alpha-2b plus ribavirin (Figure 2). 
The pooled rate of relapse was 28% (95% CI, 26%–30%) 
for naïve patients treated with peginterferon alpha-2a plus 
ribavirin for 48 weeks, and 23% (95% CI, 21%–25%) for 
those treated with peginterferon alpha-2b plus ribavirin for 
48 weeks, and 28% (95% CI: 26%–30%) for those treated 
with peginterferon alpha-2b plus ribavirin for 48 weeks. The 
pooled discontinuation rate was 23% (95% CI: 21%–24%) 
and 19% (95% CI: 17%–21%) for naïve patients treated 
with peginterferon alpha-2a plus ribavirin and peginterferon 
alpha-2b plus ribavirin, respectively, for 48 weeks.
 All eight trials assessing peginterferon alpha-2a plus 
ribavirin among treatment-experienced patients provided data 
on SVR;4–9,24,25 two also provided data on the rate of relapse,7,9 
and three also provided data on treatment discontinuations.7–9 
All six trials assessing peginterferon alpha-2b plus ribavirin 
among treatment-experienced patients provided data on 
SVR;24,25,28–31 one also provided data on the rate of relapse,28 
Table 3 Fixed-effects proportional meta-analysis of sustained virologic response, relapse, and discontinuation for treatment-naïve 
patients
Treatment  
duration
Sustained virologic response Relapse Discontinuation
Arms Proportion 
(95% CI)
I2 
(95% CI)
Arms Proportion 
(95% CI)
I2 
(95% CI)
Arms Proportion 
(95% CI)
I2 
(95% CI)
Peginterferon alpha-2a plus ribavirin
48 weeks 18 47%  
(45%–48%)
59%  
(21%–74%)
11 28%  
(26%–30%)
20%  
(0%–60%)
12 23%  
(21%–24%)
96%  
(95%–96%)
Peginterferon alpha-2b plus ribavirin
48 weeks 13 40%  
(38%–41%)
35%  
(0%–65%)
9 23%  
(21%–25%)
76%  
(48%–86%)
7 19%  
(17%–21%)
96.7%  
(95%–97%)
Abbreviation: CI, confidence interval.
Panel A
Peginterferon alpha-2a plus ribavirin
Proportion meta-analysis plot [fixed effects]
0.2 0.4 0.6 0.8
Combined 0.47 (0.45, 0.48)
Jacobson et al16 0.44 (0.39, 0.49)
Zeuzem et al22 0.51 (0.46, 0.56)
Rumi et al26 0.48 (0.38, 0.59)
Reddy et al19 0.43 (0.36, 0.50)
Mendez-Navarro et al18 0.40 (0.28, 0.53)
Marcellin et al17 0.44 (0.37, 0.51)
Ferenci et al12 0.51 (0.42, 0.60)
Roberts et al20 0.50 (0.45, 0.55)
McHutchison et al3 0.41 (0.30, 0.53)
McHutchison et al1 0.41 (0.38, 0.44)
Hezode et al15 0.46 (0.35, 0.58)
Zeuzem et al23 0.58 (0.48, 0.67)
von Wagner et al21 0.53 (0.47, 0.58)
Diago et al10 0.48 (0.43, 0.52)
Yenice et al27 0.49 (0.32, 0.66)
Ferenci et al11 0.52 (0.41, 0.62)
Hadziyannis et al14 0.52 (0.46, 0.58)
Fried et al13 0.46 (0.41, 0.52)
proportion (95% confidence interval)
Panel B
Peginterferon alpha-2b plus ribavirin
Proportion meta-analysis plot [fixed effects]
0.00 .2 0.40 .6 0.8
Combined 0.40 (0.38, 0.41)
Poordad et al2 0.40 (0.35, 0.45)
Rumi et al26 0.32 (0.23, 0.43)
Poordad et al37 0.27 (0.17, 0.39)
Kwo et al36 0.38 (0.28, 0.48)
Buti et al34 0.43 (0.32, 0.54)
McHutchison et al7 0.40 (0.37, 0.43)
Berg et al33 0.48 (0.41, 0.55)
Benhamou et al32 0.42 (0.35, 0.48)
Sjogren et al40 0.41 (0.24, 0.61)
Shiffman et al39 0.29 (0.17, 0.44)
Jacobson et al35 0.39 (0.36, 0.41)
Yenice et al27 0.35 (0.20, 0.53)
Scotto et al38 0.50 (0.30, 0.70)
proportion (95% confidence interval)
Figure 2 Fixed-effects proportional meta-analysis of sustained virologic response for treatment naïve-patients provided peginterferon alpha-2a plus ribavirin (panel A) or 
peginterferon alpha-2b plus ribavirin (panel B) for 48 weeks.
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and one provided data on treatment discontinuations.28 
Table 4 shows the results of the fixed-effects proportional 
meta-analysis of SVR, relapse, and discontinuation for 
treatment-experienced patients (refer to the Appendix for 
the random-effects models). Pooled SVR estimates for 
experienced patients treated with peginterferon alpha-2a 
plus ribavirin and peginterferon alpha-2b plus ribavirin for 
48 weeks were 12% (95% CI: 10%–14%) and 16% (95% 
CI: 12%–20%), respectively (Figure 3). The pooled rate 
of relapse was 60% (95% CI: 49%–70%) for experienced 
patients treated with peginterferon alpha-2a plus ribavirin for 
48 weeks, and 33% (95% CI: 21%–46%) for those treated 
with peginterferon alpha-2b plus ribavirin for 48 weeks. 
Discontinuation of all treatments occurred in 40% (95% CI: 
35%–45%) and 71% (95% CI: 64%–78%) of experienced 
patients treated with peginterferon alpha-2a plus ribavirin 
and peginterferon alpha-2b plus ribavirin, respectively, for 
48 weeks.
Three trials provided data on SVR in head-to-head 
evaluations of peginterferon alpha-2a plus ribavirin and 
peginterferon alpha-2b plus ribavirin among treatment-naïve 
patients.1,26,27 Another two trials provided this data in head-
to-head evaluations of peginterferon alpha-2a plus ribavirin 
and peginterferon alpha-2b plus ribavirin among treatment-
experienced patients.24,25 Table 5 presents the results of the 
fixed-effects direct comparison meta-analysis of SVR for 
patients treated with peginterferon alpha-2a plus ribavirin 
and peginterferon alpha-2b plus ribavirin for 48 weeks (refer 
to the Appendix for the random-effects model). This analysis 
shows that there are no differences between peginterferon 
alpha-2a plus ribavirin and peginterferon alpha-2b plus 
ribavirin in terms of SVR for both treatment-naïve patients 
and treatment-experienced patients. There were insufficient 
data available to allow for a direct comparison of peginter-
feron alpha-2a plus ribavirin and peginterferon alpha-2b plus 
ribavirin for relapse and discontinuation of treatment.
Discussion
The results of the current study indicate that 47% of 
treatment-naïve patients provided with peginterferon   
Table  4  Fixed-effects  proportional  meta-analysis  of  sustained  virologic  response,  relapse,  and  discontinuation  for  treatment-
experienced patients
Treatment  
duration
Sustained virologic response Relapse Discontinuation
Arms Proportion 
(95% CI)
I2 
(95% CI)
Arms Proportion 
(95% CI)
I2 
(95% CI)
Arms Proportion 
(95% CI)
I2 
(95% CI)
Peginterferon alpha-2a plus ribavirin
48 weeks 8 12%  
(10%–14%)
86.7%  
(77%–92%)
2 60%  
(49%–70%)
NA 3 40%  
(35%–45%)
96%  
(94%–97%)
Peginterferon alpha-2b plus ribavirin
48 weeks 1 16%  
(12%–20%)
0%  
(0%–61%)
1 33%  
(21%–46%)
NA 1 71%  
(64%–78%)
NA
Abbreviations: CI, confidence interval; NA, not applicable.
Panel A
Peginterferon alpha-2a plus ribavirin
Proportion meta-analysis plot [fixed effects]
0.0 0.2 0.4 0.6 0.8
Combined 0.12 (0.10, 0.14)
Zeuzem et al9 0.17 (0.11, 0.24)
McHutchison et al1 0.14 (0.08, 0.22)
Rustgi et al8 0.05 (0.02, 0.11)
Jensen et al6 0.06 (0.04, 0.09)
Scotto et al25 0.18 (0.08, 0.32)
Scotto et al24 0.11 (0.03, 0.25)
Berg et al4 0.51 (0.34, 0.69)
Herrine et al5 0.28 (0.12, 0.49)
Proportion (95% confidence interval)
Panel B
Peginterferon alpha-2b plus ribavirin
Proportion meta-analysis plot [fixed effects]
0.0 0.2 0.40 .6 0.8 1.0
Combined 0.161 (0.123, 0.204)
Bacon et al28 0.213 (0.129, 0.318)
Scotto et al25 0.128 (0.048, 0.257)
Scotto et al24 0.100 (0.028, 0.237)
Marcellin et al29 0.333 (0.008, 0.906)
Maynard et al31 0.122 (0.060, 0.213)
Mathew et al30 0.186 (0.097, 0.309)
Proportion (95% confidence interval)
Figure 3 Fixed-effects proportional meta-analysis of sustained virologic response for treatment experienced-patients provided peginterferon alpha-2a plus ribavirin (panel A) 
or peginterferon alpha-2b plus ribavirin (panel B) for 48 weeks.
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alpha-2a plus ribavirin for 48 weeks achieved a SVR 
compared to 40% of treatment-naïve patients provided 
with peginterferon alpha-2b plus ribavirin for 48 weeks. 
For   treatment-experienced patients, 12% dosed with peginter-
feron alpha-2a plus ribavirin for 48 weeks achieved a SVR 
compared to 16% who received peginterferon alpha-2b plus 
ribavirin. Among the subset of trials that included head-to-
head evaluations of peginterferon alpha-2a plus ribavirin 
and peginterferon alpha-2b plus ribavirin, the current study’s 
direct meta-analysis revealed no significant differences 
between treatments.
The current study’s results indicate that a greater pro-
portion of treatment-naïve patients receiving peginterferon 
alpha-2a plus ribavirin relapsed, when compared to those 
dosed with peginterferon alpha-2b plus ribavirin (28% 
and 23%, respectively). Similarly, a greater proportion of 
treatment-experienced patients relapsed following peginter-
ferion alpha-2a plus ribavirin as compared to peginterferion 
alpha-2b plus ribavirin (60% and 33%, respectively). A low 
relapse rate is desirable following completion of a long and 
difficult course of antiviral therapy so this characteristic is a 
key parameter guiding the selection of peginterferon alpha.
The proportion of treatment-naïve patients discontinu-
ing therapy was similar among peginterferon alpha-2a plus 
  ribavirin recipients and those dosed with peginterferon alpha-
2b plus ribavirin (23% and 19%, respectively). In contrast, the 
proportion of treatment-experienced patients discontinuing 
therapy was lower among those provided with peginterferon 
alpha-2a plus ribavirin than those   provided peginterferon 
alpha-2b plus ribavirin (40% and 71%,   respectively). It 
appears that this difference is   primarily driven by greater 
on-treatment virologic clearance with peginterferon alpha-
2a and, as a consequence, fewer patients interrupting their 
therapy for viral non-response criteria.
DAAs in combination with peginterferon alpha and 
ribavirin have dramatically improved SVR rates in genotype 
1-infected treatment recipients.2,3 Although the individual 
DAA used contributes significantly to the likelihood of 
success, peginterferon alpha plays a critical role in early 
virologic response and treatment outcomes. It is plausible that 
specific peginterferon alpha characteristics, including slope 
of early viral decay, timing of viral clearance, and relapse rate, 
may all influence the likelihood of success with DAA therapy 
utilizing a peginterferon alpha backbone. In the IDEAL study, 
a higher proportion of peginterferon alpha-2a recipients 
achieved early virologic clearance.1 This may be important 
in minimizing the likelihood of DAA resistance developing 
during the early period of combination therapy dosing. A 
lower relapse rate was observed with   peginterferon alpha-2b 
recipients. It remains to be determined whether this is also 
seen when combined with DAA therapy.   Preliminary stud-
ies with boceprevir and telaprevir suggest that the impact of 
individual peginterferon alphas may be minimal.46,80 However, 
larger studies are required to fully resolve this question.
There are limitations to the current study’s analysis 
that should be considered when interpreting these results. 
Although there were large numbers of patients enrolled in 
many of the included trials, the power to differentiate across 
interventions may be a limitation. Data were combined from 
multiple trials which were not identical in their recruitment 
procedures, study design, or analysis plans. However, this is 
true of all meta-analyses,81 and medical professionals were 
consulted at the outset to ensure that it was appropriate to pool 
these trials. The analysis of treatment-experienced patients is 
limited in that outcomes were not separately assessed for prior 
relapsers and null responders. However, in non-trial clinical 
practice, the history of prior on-treatment virologic response 
to treatment is often incomplete or missing. Therefore, the 
composite estimates provided for treatment-experienced 
patients in the current analysis are of clinical utility.
The current study’s evaluation of head-to-head trials 
suggest equivalence in terms of SVR for those provided 
with peginterferon alpha-2a plus ribavirin or peginterferon 
alpha-2b plus ribavirin. However, the pooled analysis sug-
gests a small benefit in terms of SVR with peginterferon 
alpha-2a plus ribavirin. This could be a result of a systemic 
Table 5 Fixed-effects direct comparison meta-analysis of sustained virologic response for patients treated with peginterferon alpha-2a 
plus ribavirin and peginterferon alpha-2b plus ribavirin
Treatment  
duration
Peginterferon alpha-2a plus ribavirin Peginterferon alpha-2b plus ribavirin Direct comparison
Arms Proportion 
(95% CI)
I2 
(95% CI)
Arms Proportion 
(95% CI)
I2 
(95% CI)
RR
Treatment-naïve patients
48 weeks 3 42% (39%–45%) 26% (0%–79%) 3 39% (36%–42%) 8% (0%–75%) 1.07 (0.97–1.18)
Treatment-experienced patients
48 weeks 2 15% (8%–24%) NA 2 12% (6%–20%) NA 1.27 (0.58–2.77)
Abbreviations: CI, confidence interval; NA, not applicable; RR, relative risk.
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bias in the design of peginterferon alpha-2a trials to recruit 
‘better patients’ for treatment (eg, less fibrosis, lower body 
weight, or more ribavirin per weight), and there may be better 
promotion of, or support for, patients to remain adherent. It is 
plausible that peginterferon alpha-2b trials are systematically 
designed to mandate more frequent or greater dose reductions 
of peginterferon alpha or ribavirin for side-effect manage-
ment, which may reduce on-treatment viral response, increase 
post treatment relapse, and reduce SVR. Furthermore, if the 
side-effect profile for peginterferon alpha-2a is ‘better’ than 
peginterferon alpha-2b, this would promote adherence and 
maximize dosing resulting in superior SVR result. All of 
these issues are difficult to control for given insufficient 
reporting of this information.
Other meta-analyses assessing head-to-head evaluations of 
peginterferon alpha-2a and peginterferon alpha-2b have found 
comparable results to the current study, where peginterferon 
alpha-2a plus ribavirin is slightly favorable to peginterferon 
alpha-2b plus ribavirin in terms of SVR.82–84 It is important to 
recognize, however, that the current meta-analysis differs from 
others in many important ways. Most notably, the inclusion 
criteria utilized in other meta-analyses were much broader 
than those of the current study, including, for example, trials 
that assessed induction-based treatment regimens, trials that 
assessed genotypes 3 and 4, and, in the case of Awad et al, 
trials that included patients coinfected with HIV .83
In conclusion, the current study identified small 
  differences in patient outcomes according to the type of 
peginterferon alpha used in the treatment of hepatitis C. 
The information provided by this study may be of relevance 
to the interpretation of trial results evaluating peginterferon 
alpha in combination with DAAs, and in the selection of 
the peginterferon alpha backbone for future combination 
therapies.
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Table A Random-effects proportional meta-analysis of sustained virologic response, relapse, and discontinuation for treatment-naïve 
patients
Treatment  
duration
Sustained virologic response Relapse Discontinuation
Arms Proportion 
(95% CI)
I2 
(95% CI)
Arms Proportion 
(95% CI)
I2 
(95% CI)
Arms Proportion 
(95% CI)
I2 
(95% CI)
Peginterferon alpha-2a plus ribavirin
48 weeks 18 48%  
(45%–50%)
59%  
(21%–74%)
11 28%  
(25%–30%)
20%  
(0%–60%)
15 26%  
(20%–34%)
96%  
(95%–96%)
Peginterferon alpha-2b plus ribavirin
48 weeks 13 40% 
 (37%–42%)
35%  
(0%–65%)
9 24%  
(19%–29%)
76%  
(48%–86%)
7 31%  
(16%–48%)
96.7%  
(95%–97%)
Abbreviation: CI, confidence interval.
Table B Random-effects proportional meta-analysis of sustained virologic response, relapse, and discontinuation for treatment-
experienced patients
Treatment  
duration
Sustained virologic response Relapse Discontinuation
Arms Proportion 
(95% CI)
I2 
(95% CI)
Arms Proportion 
(95% CI)
I2 
(95% CI)
Arms Proportion 
(95% CI)
I2 
(95% CI)
Peginterferon alpha-2a plus ribavirin
48 weeks 8 17%  
(9%–25%)
86.7%  
(77%–92%)
2 60%  
(48%–71%)
NA 3 40%  
(15%–68%)
96%  
(94%–97%)
Peginterferon alpha-2b plus ribavirin
48 weeks 1 16%  
(12%–20%)
0%  
(0%–61%)
1 33%  
(21%–46%)
NA 1 71%  
(64%–78%)
NA
Abbreviations: CI, confidence interval; NA, not applicable.
Table C Random-effects direct comparison meta-analysis of sustained virologic response for patients treated with peginterferon 
alpha-2a plus ribavirin and peginterferon alpha-2b plus ribavirin
Treatment  
duration
Peginterferon alpha-2a plus ribavirin Peginterferon alpha-2b plus ribavirin Direct comparison
Arms Proportion 
(95% CI)
I2 
(95% CI)
Arms Proportion 
(95% CI)
I2 
(95% CI)
RR
Treatment-naïve patients
48 weeks 3 43% (38%–48%) 26% (0%–79%) 3 39% (35%–42%) 8% (0%–75%) 1.21 (0.91–1.60)
Treatment-experienced patients
48 weeks 2 15% (8%–24%) NA 2 12% (6%–20%) NA 1.27 (0.58–2.78)
Abbreviations: CI, confidence interval; NA, not applicable; RR, relative risk.
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